Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-203 in inherited epidermolysis bullosa
NCT03468322Phase 2Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AC-203 in Epidermolysis Bullosa (EB), sponsored by TWi Biotechnology, Inc.. Started Oct 2018; status: completed.
02
Drugs
AC-203
03
Conditions
Epidermolysis Bullosa (EB)
Beyond the preview
Go deeper on NCT03468322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468322.